Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy

Marianna Rossi et al. Emerg Infect Dis. 2021 May.

Abstract

Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) has been endemic in Italy since 2013. In a multicenter cohort study, we investigated various aspects of KPC-Kp among patients, including 15-day mortality rates and delays in adequate therapy. Most (77%) KPC-Kp strains were sequence type (ST) ST512 or ST307. During 2017, KPC-Kp prevalence was 3.26 cases/1,000 hospitalized patients. Cumulative incidence of KPC-Kp acquired >48 hours after hospital admission was 0.68% but varied widely between centers. Among patients with mild infections and noninfected colonized patients, 15-day mortality rates were comparable, but rates were much higher among patients with severe infections. Delays of >4 days in receiving adequate therapy more frequently occurred among patients with mild infections than those with severe infections, and delays were less common for patients with known previous KPC-Kp colonization. Italy urgently needs a concerted surveillance system to control the spread of KPC-Kp.

Keywords: CRE; Carbapenem resistance; Enterobacteriaceae; Italy; KPC-Kp; Klebsiella pneumoniae; antimicrobial resistance; bacteria; healthcare-associated infections; mortality rates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of network of healthcare centers participating in a study of Klebsiella pneumoniae–carbapenemase producing K. pneumoniae (KPC-Kp), Italy, 2016–2018. The KPC-Kp network included 15 hospitals. Patients were included when KPC-Kp was diagnosed and excluded for various reasons. Hospitals were included when they submitted KPC-Kp–confirmed isolates and excluded from analysis when had no confirmed patients or did not enroll all confirmed patients. KPC-Kp, Klebsiella pneumoniae–carbapenemase producing K. pneumoniae.
Figure 2
Figure 2
Phylogenetic tree of 989 Klebsiella pneumoniae genomes isolated at hospitals participating in the KPC-producing K. pneumoniae (KPC-Kp) study, Italy. The key shows the number of isolates included in the study provided by each center; 2 samples (1 from each from hospitals A and I) were excluded because the total quality of the assemblies was not sufficient to have high confidence in the SNPs called through all the genome (total coverage <30). Inner circle shows the KPC-Kp mechanism identified; middle circle shows hospitals from which strains were isolated; and the outer circle the shows identified STs. The whole genome core single-nucleotide polymorphisms (SNPs) were extracted from the 989 K. pneumoniae genome assemblies by using kSNP3.0 (https://sourceforge.net/projects/ksnp). Parametric maximum-likelihood estimation (general time-reversible plus gamma distribution plus invariable sites) analysis with 1,000 bootstrap estimates was used to infer the phylogeny. We used IQ-TREE (http://www.iqtree.org) to generate the tree and iTOL (https://itol.embl.de) to draw the tree. Major STs are represented by branch colors; ST512 and ST307 were the predominant STs. Major branches have bootstrap values >0.75 for branch support. Scale bar indicates nucleotide substitutions per site. KPC, Klebsiella pneumoniae–carbapenemase; ST, sequence type.

References

    1. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8:460–9. 10.1080/21505594.2016.1222343 - DOI - PMC - PubMed
    1. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36. 10.1016/S1473-3099(09)70054-4 - DOI - PubMed
    1. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–7. 10.1093/cid/cir202 - DOI - PubMed
    1. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50. 10.1093/cid/cis588 - DOI - PubMed
    1. Stewardson AJ, Marimuthu K, Sengupta S, Allignol A, El-Bouseary M, Carvalho MJ, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019;19:601–10. 10.1016/S1473-3099(18)30792-8 - DOI - PubMed

Publication types